REPL Replimune Group Inc

Price (delayed)

$29.01

Market cap

$1.36B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.84

Enterprise value

$1.2B

Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary ...

Highlights
Replimune Group's debt has decreased by 23% YoY
The company's equity has surged by 72% YoY but it fell by 4% QoQ
The net income has contracted by 47% YoY but it has grown by 22% from the previous quarter
The company's EPS fell by 11% YoY and by 5% QoQ

Key stats

What are the main financial stats of REPL
Market
Shares outstanding
46.77M
Market cap
$1.36B
Enterprise value
$1.2B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.82
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$61.19M
EBITDA
-$59.35M
Free cash flow
-$66.36M
Per share
EPS
-$1.84
Free cash flow per share
-$1.28
Book value per share
$10.28
Revenue per share
$0
TBVPS
$10.09
Balance sheet
Total assets
$523.72M
Total liabilities
$44.7M
Debt
$33.13M
Equity
$479.02M
Working capital
$449.51M
Liquidity
Debt to equity
0.07
Current ratio
30.87
Quick ratio
30.81
Net debt/EBITDA
2.71
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-13.1%
Return on equity
-14.4%
Return on invested capital
-19.1%
Return on capital employed
-12%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

REPL stock price

How has the Replimune Group stock price performed over time
Intraday
0.24%
1 week
-3.78%
1 month
-12.22%
1 year
-33.14%
YTD
-23.96%
QTD
-2.13%

Financial performance

How have Replimune Group's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$62.15M
Net income
-$63.4M
Gross margin
N/A
Net margin
N/A
The net income has contracted by 47% YoY but it has grown by 22% from the previous quarter
The operating income has declined by 37% year-on-year but it has increased by 22% since the previous quarter

Growth

What is Replimune Group's growth rate over time

Valuation

What is Replimune Group stock price valuation
P/E
N/A
P/B
2.82
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 11% YoY and by 5% QoQ
The company's equity has surged by 72% YoY but it fell by 4% QoQ
REPL's price to book (P/B) is 17% lower than its last 4 quarters average of 3.4

Efficiency

How efficient is Replimune Group business performance
REPL's ROE is up by 35% YoY and by 31% QoQ
Replimune Group's return on assets has increased by 29% QoQ and by 27% YoY
Replimune Group's return on invested capital has increased by 27% QoQ and by 10% YoY

Dividends

What is REPL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for REPL.

Financial health

How did Replimune Group financials performed over time
The total assets has soared by 59% YoY but it is down by 3.6% from the previous quarter
REPL's current ratio is up by 37% YoY but it is down by 7% QoQ
Replimune Group's debt is 93% less than its equity
The company's equity has surged by 72% YoY but it fell by 4% QoQ
The debt to equity has dropped by 56% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.